Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.980 −2.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0% OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.980 −2.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0%
M&A / Property Routine +

Quantum Biopharma signs LOI for phase 2 MS trial

Court Clears Path for $700M Spoofing Suit, But Cash Burn and Clinical Execution Remain the Real Hurdles

By The Northwire Desk — AI Analysis Mar 30, 2026 · 18:07 QNTM · 5.96 Quantum Biopharma Ltd
Executive Summary
  • The U.S. District Court for the Southern District of New York largely denied a joint motion to dismiss filed by CIBC World Markets and RBC Dominion Securities
  • The ruling allows Quantum Biopharma’s lawsuit alleging illegal stock spoofing and market manipulation between January 1, 2020 and August 15, 2024 to proceed to the discovery and merits phase
  • The company is seeking up to USD $700 million in damages for alleged violations of Sections 10(b), 9(a) and Rule 10b-5 of the Securities Exchange Act of 1934
  • The decision removes an early procedural barrier but does not constitute a finding of liability, settlement, or final judgment
  • The case remains on contingency with external counsel, meaning no immediate legal fee outlay for the company
Material Impact
  • The ruling is a procedural milestone rather than a fundamental value driver
  • Surviving a motion to dismiss is an expected step in complex securities litigation and does not guarantee a payout or settlement
  • The $700 million claim is aspirational and highly contingent on proving intent, causation, and damages in a notoriously difficult area of financial law
  • Management has heavily promoted the litigation narrative since late 2025, meaning the market has likely already priced in the possibility of the case advancing
  • No immediate cash inflow or balance sheet improvement occurs from this ruling
  • The primary impact is psychological and narrative-driven, potentially stabilizing short-term sentiment but not altering the company’s core operational or financial trajectory
QNTM · Price
Company Overview
  • Quantum Biopharma is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases and consumer health
  • Flagship asset: Lucid-MS (Lucid-21-302), a first-in-class, non-immunomodulatory neuroprotective compound designed to inhibit demyelination in multiple sclerosis
  • Phase 1 oral toxicity and toxicokinetic studies completed with no safety signals; oral formulation selected for Phase 2
  • IND application submitted to the FDA in March 2026; Phase 2 trial targeted for Q2 2026 initiation with interim data expected by Q4 2026
  • Secondary asset: unbuzzd, a dietary supplement licensed to Unbuzzd Wellness Inc. that claims to accelerate alcohol metabolism and reduce hangover symptoms
  • Quantum retains a 19.86% equity stake in Unbuzzd and receives a 7% royalty on sales until $250 million cumulative, dropping to 3% thereafter
  • The company also holds a diversified digital asset portfolio (Bitcoin, ETH, SOL, etc.) and minor equity investments
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other